DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for Daily Newsletter Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE TUE, FEB 27, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon!  Drugmakers aren't just racing to develop drugs that treat obesity. They're also competing to expand the uses of those weight loss treatments, including for a severe form of liver disease.   Some drugmakers – including the dominant players in the market, Novo Nordisk and Eli Lilly – have already demonstrated the drugs' ability to help patients shed unwanted pounds and regulate blood sugar.   Now, they aim to show the treatments can bring additional health benefits. Doing so could unlock even more revenue from the booming market, and expand the limited insurance coverage for those treatments, most of which cost close to $1,000 per month.    The competition heated up